These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 22087278)
1. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278 [TBL] [Abstract][Full Text] [Related]
2. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371 [TBL] [Abstract][Full Text] [Related]
3. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats. Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664 [TBL] [Abstract][Full Text] [Related]
4. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736 [TBL] [Abstract][Full Text] [Related]
5. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941 [TBL] [Abstract][Full Text] [Related]
6. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808 [TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170 [TBL] [Abstract][Full Text] [Related]
8. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals. Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026 [TBL] [Abstract][Full Text] [Related]
9. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat. Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448 [TBL] [Abstract][Full Text] [Related]
10. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. Yashiro H; Tsujihata Y; Takeuchi K; Hazama M; Johnson PR; Rorsman P J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100 [TBL] [Abstract][Full Text] [Related]
11. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Lin DC; Guo Q; Luo J; Zhang J; Nguyen K; Chen M; Tran T; Dransfield PJ; Brown SP; Houze J; Vimolratana M; Jiao XY; Wang Y; Birdsall NJ; Swaminath G Mol Pharmacol; 2012 Nov; 82(5):843-59. PubMed ID: 22859723 [TBL] [Abstract][Full Text] [Related]
12. Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes. Yoon J; Lee DG; Song H; Hong D; Park JS; Hong C; An KM; Lee JW; Park JT; Yoon H; Tak J; Kim SG Biomed Pharmacother; 2024 Aug; 177():117044. PubMed ID: 38941892 [TBL] [Abstract][Full Text] [Related]
13. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models. Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688 [TBL] [Abstract][Full Text] [Related]
14. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity. Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471 [TBL] [Abstract][Full Text] [Related]
15. AMG 837: a potent, orally bioavailable GPR40 agonist. Houze JB; Zhu L; Sun Y; Akerman M; Qiu W; Zhang AJ; Sharma R; Schmitt M; Wang Y; Liu J; Liu J; Medina JC; Reagan JD; Luo J; Tonn G; Zhang J; Lu JY; Chen M; Lopez E; Nguyen K; Yang L; Tang L; Tian H; Shuttleworth SJ; Lin DC Bioorg Med Chem Lett; 2012 Jan; 22(2):1267-70. PubMed ID: 22217876 [TBL] [Abstract][Full Text] [Related]
16. In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469. Urban C; Hamacher A; Partke HJ; Roden M; Schinner S; Christiansen E; Due-Hansen ME; Ulven T; Gohlke H; Kassack MU Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1021-30. PubMed ID: 23861168 [TBL] [Abstract][Full Text] [Related]
17. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production. Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610 [TBL] [Abstract][Full Text] [Related]
18. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249 [TBL] [Abstract][Full Text] [Related]
19. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176 [TBL] [Abstract][Full Text] [Related]
20. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists. Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]